vilanterol
Jump to navigation
Jump to search
Indications
- used in combination with umeclidinium in Anoro, an inhaler for treatment of COPD
* safe for patients with cardiovascular disease
Mechanism of action
More general terms
Component of
References
- ↑ Physician's First Watch, May 1, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
FDA News Release: May 10, 2013 FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease - ↑ Vestbo J, Anderson JA, Brook RD et al Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016 Apr 30;387(10030):1817-26. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27203508
Brusselle G. Vilanterol fluticasone and mortality in comorbid COPD GOLD B. Lancet. 2016 Apr 30;387(10030):1791-2. Epub 2016 Apr 28. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27203487